NCT03627026View on ClinicalTrials.gov

Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients

NACompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

September 8, 2023

Study Completion Date

June 3, 2024

Conditions
Melanoma
Interventions
OTHER

Blood samples will be collected at different time points:

"* Baseline~* Week 6 Day 1~* Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center."

Trial Locations (2)

31059

Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse

44093

Chu Nantes, Nantes

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER

NCT03627026 - Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients | Biotech Hunter | Biotech Hunter